Yu Joshua Cao
Affiliations: | 2013-2016 | Chemistry | Scripps Research Institute, La Jolla, La Jolla, CA, United States |
2017- | Chemical Biology and Biotechnology | Peking University Shenzhen Graduate School |
Google:
"Yu Cao"Mean distance: (not calculated yet)
Parents
Sign in to add mentorGang Bai | grad student | 2001-2007 | Nankai University |
Michael G. Rosenblum | grad student | 2007-2013 | University of Texas, MD Anderson Cancer Center |
Peter G. Schultz | post-doc | 2013-2016 | Scripps Institute |
Children
Sign in to add traineeZhidong Wang | grad student | 2018-2022 | Peking University |
Lijun Zhao | grad student | 2018-2022 | Peking University |
Shuhong Li | grad student | 2019-2023 | Peking University |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
He M, Zhang D, Cao Y, et al. (2023) Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects. Heliyon. 9: e19147 |
Cao Y, Efetov SK, He M, et al. (2023) Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. Archivum Immunologiae Et Therapiae Experimentalis. 71: 19 |
Wen J, Huang Q, Yao J, et al. (2023) Focusing on scRNA-seq-Derived T Cell-Associated Genes to Identify Prognostic Signature and Immune Microenvironment Status in Low-Grade Glioma. Mediators of Inflammation. 2023: 3648946 |
Jiang H, Suo H, Gao L, et al. (2023) Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer. International Immunopharmacology. 118: 110038 |
Qiu Y, Qi Z, Wang Z, et al. (2022) EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models. Oncology Reports. 49 |
Liu D, Qi X, Wei X, et al. (2022) A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy. Theranostics. 12: 7788-7803 |
Zhao L, Li S, Wei X, et al. (2022) A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood |
Xia Y, Li X, Yang L, et al. (2021) Development of thermostable sucrose phosphorylase by semi-rational design for efficient biosynthesis of alpha-D-glucosylglycerol. Applied Microbiology and Biotechnology |
Cao YJ, Yu C, Wu KL, et al. (2021) Synthesis of precision antibody conjugates using proximity-induced chemistry. Theranostics. 11: 9107-9117 |
Bloom JA, Sekigami Y, Young R, et al. (2021) Discordance in Oncotype DX Breast Recurrence Score Results for Bilateral Breast Cancer. Annals of Surgical Oncology |